UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 22,078 shares, a growth of 8,231.3% from the May 14th total of 265 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 59,267 shares, the days-to-cover ratio is presently 0.4 days.

UCB Price Performance

OTCMKTS:UCBJY traded up $1.58 during midday trading on Tuesday, hitting $151.74. The stock had a trading volume of 18,290 shares, compared to its average volume of 37,792. UCB has a one year low of $89.00 and a one year high of $168.76. The stock has a 50-day moving average of $145.27 and a 200 day moving average of $146.65. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20.

Analysts Set New Price Targets

UCBJY has been the subject of a number of research analyst reports. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 13th. Wolfe Research upgraded UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.